Welcome to our dedicated page for Dogwood Therapeutics news (Ticker: DWTX), a resource for investors and traders seeking the latest updates and insights on Dogwood Therapeutics stock.
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) is a development-stage biopharmaceutical company whose news flow centers on the clinical and corporate progress of its pain and neuropathy programs. The company regularly issues updates on Halneuron®, its lead non-opioid NaV 1.7 analgesic in Phase 2b development for chemotherapy-induced neuropathic pain (CINP), as well as on SP16 IV, its LRP1 agonist candidate with potential to treat neuropathy and repair nerve damage following chemotherapy.
News items for DWTX commonly include interim clinical trial readouts, enrollment milestones and study design details for the HALT-CINP Phase 2b trial, where Dogwood reports on safety, tolerability and pain improvement data compared with placebo. The company also provides announcements on regulatory designations, such as FDA fast track status for Halneuron® in CINP, and on preclinical findings that describe mechanisms like NaV 1.7 modulation and LRP1-mediated anti-inflammatory and neural repair activity.
Investors following Dogwood’s news can expect coverage of financing transactions, including registered direct offerings, concurrent private placements and equity incentive plan approvals disclosed through press releases and Form 8-K filings. The company’s communications also highlight licensing deals, such as the exclusive, royalty-free global license for SP16 IV, and describe how these transactions expand the research pipeline in cancer-related pain and chemotherapy-induced neuropathy.
Additional news categories include participation in investor conferences and scientific meetings, where Dogwood’s management discusses the Halneuron® pain research program, synthetic manufacturing advances and the antiviral platform involving IMC-1 and IMC-2 for fibromyalgia and Long-COVID. For readers interested in DWTX, this news page aggregates these clinical, regulatory, financial and partnership developments in one place for ongoing reference.
Dogwood Therapeutics (Nasdaq: DWTX) announced it has reached over 50% enrollment in the HALT-CINP Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain and remains on track for top-line results in Q3 2026.
An independent review of an earlier interim cohort reported separation from placebo on pain improvement and a low overall dropout rate (~4%). The randomized trial enrolls at ~30 U.S. sites with a 28-day follow-up and primary endpoint at week four.
Dogwood Therapeutics (NASDAQ: DWTX) announced registered and private offerings to raise up to $12.5 million in upfront gross proceeds and the potential for an additional $14.4 million upon warrant exercises, for aggregate financings tied to issuance of 4,386,037 common shares (or pre-funded warrants) and detachable warrants. Securities are priced at-the-market under Nasdaq rules at a combined purchase price of $2.85 and warrant exercise price of $3.28. Proceeds are earmarked to advance Halneuron through Phase 2b final readout and support further development and working capital.
Dogwood Therapeutics (Nasdaq: DWTX) reported a positive interim analysis from 97 patients in its Phase 2b study of Halneuron for chemotherapy induced neuropathic pain (CINP) on Dec 22, 2025. An independent committee found Halneuron-treated patients separated from placebo on pain improvement over four weeks. The company projects top-line results in Q3 2026 and enrollment trends that provide ~80%–85% statistical power. The interim cohort had an average CINP duration of 5 years, with 67% on stable background pain meds; overall dropout was ~4.4%. The company says safety and tolerability remain encouraging, and positive Phase 2b outcomes could support a Phase 3 registration program.
Dogwood Therapeutics (Nasdaq: DWTX) filed a new composition of matter intellectual property application for a fully synthetically manufactured Halneuron® on December 2, 2025. The company says the synthetic process delivers higher manufacturing yields and lower costs versus naturally harvested Halneuron® and is planned for use in Phase 3 development and commercialization. If the IP is granted, Dogwood projects the exclusivity period could extend to 2045, before any additional patent term restoration.
Dogwood (Nasdaq:DWTX) announced it has enrolled the first 100 patients in the HALT-CINP Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain as of November 11, 2025. The company says early termination rates remain low among the first 80 completers, suggesting tolerability. A prespecified interim sample-size analysis is on track for Q4 2025 to evaluate whether the planned 200-patient sample remains adequate. The study randomizes patients to Halneuron® or placebo, delivers 8 subcutaneous doses over 14 days, follows patients for 28 days, and is running at ~25 US sites, with final data targeted for mid-2026.
Dogwood Therapeutics (Nasdaq: DWTX) reported Q3 2025 results and strategic updates on Nov 6, 2025. Key operational items: 100 patients enrolled in the Halneuron® Phase 2b trial with 80 completing treatment, and the prespecified interim analysis remains on track for Q4 2025 with final 200‑patient data expected in H2 2026. The company closed an exclusive worldwide, royalty‑free license to develop SP16 in an all‑stock transaction. Financials: Q3 R&D expense was $14.5M (vs $0.5M prior year) driven by a $12.0M acquired in‑process R&D charge; net loss was $15.7M or $8.20 per share. Cash of $10.1M provides runway through Q1 2026.
Dogwood Therapeutics (Nasdaq:DWTX) announced it will report third quarter 2025 financial results on Thursday, November 6, 2025 before market open.
The company is a development-stage biotechnology firm focused on new medicines to treat pain and neuropathy. No financial metrics or guidance were included in the announcement.
Dogwood Therapeutics (Nasdaq:DWTX) announced that CEO Greg Duncan will participate at the Maxim Growth Summit on October 22–23, 2025 at the Hard Rock Hotel in New York City.
Mr. Duncan will be available for one-on-one meetings with institutional investors and will meet with senior Maxim analysts during the event. For agenda and registration details, visit www.maximgrp.com/2025-growth-summit.
Dogwood Therapeutics (Nasdaq:DWTX) announced that its Chief Medical Officer will present an overview of the Halneuron® (tetrodotoxin) pain research program at the 19th Annual Pain Therapeutics Summit on October 14, 2025.
Halneuron is a highly purified TTX formulation in development for chemotherapy‑induced neuropathic pain (CINP). A preclinical CINP study found Halneuron and VX‑548 each rapidly suppressed mechanical allodynia, with Halneuron showing comparable or greater pain reduction and the combination showing no additive benefit. Over 700 patients have received TTX in human studies. Halneuron showed pain reduction in prior Phase 2 studies and is being evaluated in a Phase 2b HALT‑CINP trial at 25 U.S. sites to assess low‑dose injectable safety and efficacy.
Dogwood Therapeutics (NASDAQ:DWTX) has secured a worldwide, royalty-free license for SP16, a first-in-class LRP1 agonist, through an all-stock transaction with Serpin Pharma. SP16 will be developed as a treatment for cancer-related pain, specifically focusing on chemotherapy-induced peripheral neuropathy (CIPN).
The National Cancer Institute has fully funded SP16's upcoming Phase 1b CIPN study, with patient enrollment expected to begin in H1 2026. SP16 has shown both anti-inflammatory and neural repair properties in preclinical research, potentially complementing Dogwood's existing drug Halneuron®, which is currently in Phase 2b trials for chemotherapy-induced neuropathic pain with interim data expected in December 2025.